Reviva Pharmaceuticals Holdings, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.4M | $-3.2M | $-3.4M | $-4.0M | $-6.1M | $-6.4M | $-6.3M | $-8.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $214.6K | $584.4K | $455.1K | $458.4K | $395.3K | $919.1K | $554.2K | $348.1K |
| Net Cash from Operating Activities | $-2.1M | $-3.8M | $-5.8M | $-5.6M | $-5.0M | $-8.2M | $-9.1M | $-4.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-184.9K | $11.6M | $7.1M | $8.4M | $10.1M | $7.3K | $17.0M | $3.6M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |